GlassScriptPrepare for your visit
Paula D Ravin
Neurology (Psychiatry & Neurology) · Los Angeles, CA · NPI 1558346130
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$211,613.88
in general payments reported to CMS, 2019-2025 · $6,488 in 2025
The $6,488 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Who reported paying
General payments only, top 6 by amount.
- Adamas Pharmaceuticals, INC. $96,050.15
- Mdd US Operations, LLC $72,531.66
- Kyowa Kirin, INC. $33,610.94
- Acadia Pharmaceuticals INC $7,902.03
- Amneal Pharmaceuticals LLC $529.64
- Abbvie INC. $271.33
Drugs and devices associated with these payments
Gocovri Nourianz Crexont Vyalev Rexulti Ingrezza Dysport Rytary Inbrija Nuplazid Ongentys
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Paula Ravin listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/252008/paula-d-ravin